Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze For The Treatment Of Acute Lymphoblastic Leukemia And Lymphoblastic Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Ligand Pharmaceuticals (NASDAQ:LGND) announced that its partner Jazz Pharmaceuticals (NASDAQ:JAZZ) has received approval from the European Commission for Enrylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma. The approval expands the market for one of Ligand's key commercial-stage products. Ligand is eligible to receive milestone payments and tiered royalties based on worldwide net sales of any products resulting from its collaboration with Jazz, including Rylaze.
September 22, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jazz Pharmaceuticals has received approval from the European Commission for Enrylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma. This approval expands the market for Jazz's product, which is likely to increase the company's revenues.
The approval of Enrylaze by the European Commission expands the market for one of Jazz Pharmaceuticals' products. This is likely to increase the company's revenues, which is positive news and is likely to have a positive impact on Jazz's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The European Commission's approval of Enrylaze, a product of Ligand's partner Jazz Pharmaceuticals, expands the market for one of Ligand's key commercial-stage products. Ligand is set to receive milestone payments and tiered royalties from worldwide net sales of any products from its collaboration with Jazz.
The approval of Enrylaze by the European Commission expands the market for one of Ligand's key products. This is likely to increase the company's revenues, especially as Ligand is set to receive milestone payments and tiered royalties from worldwide net sales of any products from its collaboration with Jazz. This positive news is likely to have a positive impact on Ligand's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100